DexCom's CONNECT Breakthrough: The 25-Million-Patient Door Is Creaking Open

A Quarter of Execution and Evidence

DexCom's second-quarter report was a double-barrel of operational excellence and clinical vindication. Revenue hit $1.31B, up 13% year-over-year (12% organic), with the U.S. up 11% and international up 19% (16% organic). Type 2 non-insulin patient starts remained near record levels, and the company raised its full-year revenue guidance to $5.18–5.25B (11–13% growth). But the headline was the CONNECT trial readout—a randomized controlled trial in type 2 patients not on insulin that delivered a 1.6% A1C reduction and a 0.9% difference versus control. As CEO Jake Leach put it: “Over the 6-month study period, we saw a 1.6% A1C improvement for the Dexcom CGM group.” — Jacob Steven Leach, President and CEO · 2026-07-30 This is Level A evidence for a population that has lacked it, and it validates the company's decade-long thesis that CGM should be standard of care for all people with diabetes.

The market has taken notice. The stock is up 44% over the past 90 days, a reflection of both the quarter and the Tempo pilot designation from the FDA—a program that could extend CGM into prediabetes screening. The DexCom CGM franchise is expanding beyond insulin users to the much larger type 2 non-insulin population, and the commercial payer momentum is already building. The company now has coverage for 7 million non-insulin type 2 patients across the four largest PBMs, and the CONNECT data only accelerates that.

The Road to 100: CMS and Beyond

The most consequential catalyst is the pending Medicare decision for non-insulin coverage. Management has submitted the CONNECT data to CMS and expects a decision before year-end, with coverage potentially effective mid-2027. Leach stated clearly:

We do expect to hear back from CMS on that decision before the end of this year. And in our plans right now, we have got it taking effect in the middle of 2027.

The Smart Basal pilot is another differentiator. It addresses the largest unmet need in insulin management—titration—and early feedback shows patients reaching optimal doses in 3 weeks versus the typical 12 weeks. Meanwhile, the G7 15-day conversion is on track to hit ~50% of the U.S. base by year-end, a tailwind that compounds with the Q2 gross margin expansion to 64.1% (up 400bps YoY).

Margins, Cash, and the Green Light for Innovation

The margin story is equally compelling. Gross margin jumped to 62.9% (non-GAAP 64.1%) as manufacturing efficiencies, scrap reduction, and the 15-day mix shift took hold. Operating leverage was even sharper: operating income grew 75%, and free cash flow generation was spectacular—$600M+ in the first half, more than double last year. Free cash flow margin reached 34%, allowing the company to execute its $1B buyback authorization—already $600M in Q2—while funding the Ireland facility that will come online later this year.

This is a turning point. The company's prior calls were dominated by execution risks and coverage uncertainty—as Jereme Sylvain noted in Q1, "the RCT may not be required for that CMS coverage" and "it is really just a matter of time." Now the evidence is in hand, coverage is expanding, and the financial model is inflecting. The margin performance is funding a pipeline that includes the G8 multi-analyte sensor and the Stello app redesign, laying the groundwork for the next decade of growth. As management highlighted, the international opportunity alone—with 60 million potential covered lives—remains vastly underpenetrated.

With the Street watching for a CMS decision and the company guiding up margins, DexCom is no longer just a diabetes-device company; it is becoming a metabolic-health platform. The 44% run-up is a start, but the real prize—Medicare's 25 million patients—is still ahead. This is a name-in-motion with a tangible catalyst, and the evidence is now in the data.